Share Price and Basic Stock Data
Last Updated: October 29, 2025, 8:40 am
| PEG Ratio | 5.21 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Colinz Laboratories Ltd operates in the pharmaceuticals sector, focusing on the production of various medicinal products. As of the latest reporting period, the company’s stock price stood at ₹39.8 with a market capitalization of ₹18.2 Cr. The company reported sales of ₹7.15 Cr for the fiscal year ending March 2023, a slight increase from ₹6.97 Cr in the previous fiscal year. However, the trailing twelve months (TTM) revenue declined to ₹6.35 Cr, indicating a potential slowdown. Quarterly sales figures showed fluctuations, with the highest quarterly sales recorded at ₹1.92 Cr in September 2022, while the most recent quarter (September 2023) saw sales of ₹1.79 Cr. This trend highlights the need for Colinz Laboratories to stabilize its revenue streams amidst the competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
Colinz Laboratories reported a net profit of ₹0.48 Cr for the year ending March 2023, an increase from ₹0.46 Cr in the previous year. The operating profit margin (OPM) stood at 8.28%, while the overall profitability metrics, including a return on equity (ROE) of 5.43% and return on capital employed (ROCE) of 6.72%, are relatively low compared to industry standards. The interest coverage ratio (ICR) was robust at 18.70x, indicating that the company can comfortably meet its interest obligations. However, the company’s cash conversion cycle (CCC) of 78.81 days suggests inefficiencies in managing working capital, particularly in inventory and receivables. The fluctuating quarterly OPM percentages, with a notable decline to 6.70% in September 2023, emphasize the need for Colinz to enhance cost management strategies to improve profitability.
Balance Sheet Strength and Financial Ratios
Colinz Laboratories maintained a conservative balance sheet with total borrowings of only ₹0.64 Cr against reserves of ₹6.96 Cr, reflecting a solid equity base. The company’s total assets stood at ₹11.82 Cr, with fixed assets valued at ₹1.70 Cr. The current ratio of 4.17x and quick ratio of 3.81x indicate strong liquidity position, allowing it to cover short-term liabilities comfortably. The price-to-book value (P/BV) ratio was recorded at 1.93x, suggesting that investors are willing to pay a premium over the book value, which is indicative of potential growth expectations. However, the enterprise value (EV) to net operating revenue ratio of 2.04x may indicate high valuation relative to its revenue generation capabilities, which could deter potential investors if not justified by future performance.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Colinz Laboratories reflects a strong promoter backing, with promoters holding 66% of the company’s equity. This stability in ownership may foster investor confidence; however, the absence of Foreign Institutional Investors (FIIs) and negligible participation from Domestic Institutional Investors (DIIs) at 0% raises questions about broader market confidence. The number of shareholders has gradually increased from 2,863 in December 2022 to 3,272 by March 2025, indicating a growing interest among retail investors. Nevertheless, the concentration of shares in the hands of promoters may limit liquidity and influence market dynamics, potentially impacting the stock’s price volatility. The public holding stood at 33.99%, suggesting some balance but still highlighting the reliance on a few key stakeholders.
Outlook, Risks, and Final Insight
Looking ahead, Colinz Laboratories faces both opportunities and risks. The consistent promoter support and strong liquidity position present a solid foundation for future growth. However, the declining revenue trend and inefficiencies in operational metrics could pose significant challenges. Additionally, the company must navigate a highly competitive pharmaceutical landscape while improving its profitability margins and operational efficiency. Risks include potential market fluctuations and regulatory changes that could impact sales and profitability. The company’s ability to innovate and adapt to market demands will be crucial in enhancing its competitive positioning. If Colinz Laboratories can leverage its strong balance sheet to invest in growth initiatives and streamline operations, it may enhance shareholder value and secure a more favorable market position. Conversely, failure to address operational inefficiencies and declining revenue could hamper its long-term growth potential.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Colinz Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 144 Cr. | 114 | 247/84.3 | 32.8 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.80 Cr. | 1.99 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,983 Cr. | 460 | 479/192 | 112 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.6 Cr. | 48.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 32.2 Cr. | 22.0 | 29.1/17.0 | 33.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,784.10 Cr | 1,180.72 | 50.39 | 194.36 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.84 | 1.92 | 1.68 | 1.72 | 1.90 | 1.79 | 1.71 | 1.63 | 1.75 | 1.86 | 1.47 | 1.45 | 1.57 |
| Expenses | 1.69 | 1.76 | 1.55 | 1.56 | 1.74 | 1.67 | 1.57 | 1.51 | 1.59 | 1.69 | 1.40 | 1.35 | 1.44 |
| Operating Profit | 0.15 | 0.16 | 0.13 | 0.16 | 0.16 | 0.12 | 0.14 | 0.12 | 0.16 | 0.17 | 0.07 | 0.10 | 0.13 |
| OPM % | 8.15% | 8.33% | 7.74% | 9.30% | 8.42% | 6.70% | 8.19% | 7.36% | 9.14% | 9.14% | 4.76% | 6.90% | 8.28% |
| Other Income | 0.04 | 0.05 | 0.04 | 0.04 | 0.04 | 0.08 | 0.05 | 0.11 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 |
| Profit before tax | 0.15 | 0.17 | 0.13 | 0.16 | 0.16 | 0.16 | 0.15 | 0.19 | 0.19 | 0.21 | 0.11 | 0.13 | 0.16 |
| Tax % | 20.00% | 29.41% | 23.08% | 18.75% | 18.75% | 25.00% | 26.67% | 31.58% | 26.32% | 23.81% | 45.45% | -23.08% | 25.00% |
| Net Profit | 0.11 | 0.12 | 0.10 | 0.13 | 0.12 | 0.12 | 0.11 | 0.14 | 0.14 | 0.16 | 0.05 | 0.15 | 0.12 |
| EPS in Rs | 0.24 | 0.26 | 0.22 | 0.28 | 0.26 | 0.26 | 0.24 | 0.31 | 0.31 | 0.35 | 0.11 | 0.33 | 0.26 |
Last Updated: August 19, 2025, 8:55 pm
Below is a detailed analysis of the quarterly data for Colinz Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1.57 Cr.. The value appears strong and on an upward trend. It has increased from 1.45 Cr. (Mar 2025) to 1.57 Cr., marking an increase of 0.12 Cr..
- For Expenses, as of Jun 2025, the value is 1.44 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.35 Cr. (Mar 2025) to 1.44 Cr., marking an increase of 0.09 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.13 Cr.. The value appears strong and on an upward trend. It has increased from 0.10 Cr. (Mar 2025) to 0.13 Cr., marking an increase of 0.03 Cr..
- For OPM %, as of Jun 2025, the value is 8.28%. The value appears strong and on an upward trend. It has increased from 6.90% (Mar 2025) to 8.28%, marking an increase of 1.38%.
- For Other Income, as of Jun 2025, the value is 0.08 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.08 Cr..
- For Interest, as of Jun 2025, the value is 0.01 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.02 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.01 Cr..
- For Depreciation, as of Jun 2025, the value is 0.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.03 Cr. (Mar 2025) to 0.04 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.16 Cr.. The value appears strong and on an upward trend. It has increased from 0.13 Cr. (Mar 2025) to 0.16 Cr., marking an increase of 0.03 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from -23.08% (Mar 2025) to 25.00%, marking an increase of 48.08%.
- For Net Profit, as of Jun 2025, the value is 0.12 Cr.. The value appears to be declining and may need further review. It has decreased from 0.15 Cr. (Mar 2025) to 0.12 Cr., marking a decrease of 0.03 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.26. The value appears to be declining and may need further review. It has decreased from 0.33 (Mar 2025) to 0.26, marking a decrease of 0.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:37 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.41 | 7.88 | 8.10 | 8.05 | 7.83 | 7.59 | 7.53 | 6.16 | 6.97 | 7.15 | 7.03 | 6.53 | 6.35 |
| Expenses | 7.07 | 7.42 | 7.65 | 7.64 | 7.48 | 7.24 | 7.22 | 5.82 | 6.38 | 6.52 | 6.49 | 6.04 | 5.88 |
| Operating Profit | 0.34 | 0.46 | 0.45 | 0.41 | 0.35 | 0.35 | 0.31 | 0.34 | 0.59 | 0.63 | 0.54 | 0.49 | 0.47 |
| OPM % | 4.59% | 5.84% | 5.56% | 5.09% | 4.47% | 4.61% | 4.12% | 5.52% | 8.46% | 8.81% | 7.68% | 7.50% | 7.40% |
| Other Income | 0.13 | 0.10 | 0.10 | 0.09 | 0.10 | 0.12 | 0.13 | 0.19 | 0.17 | 0.15 | 0.28 | 0.30 | 0.32 |
| Interest | 0.08 | 0.12 | 0.12 | 0.12 | 0.08 | 0.10 | 0.07 | 0.09 | 0.08 | 0.05 | 0.04 | 0.04 | 0.05 |
| Depreciation | 0.26 | 0.30 | 0.28 | 0.27 | 0.22 | 0.22 | 0.19 | 0.19 | 0.20 | 0.13 | 0.13 | 0.13 | 0.13 |
| Profit before tax | 0.13 | 0.14 | 0.15 | 0.11 | 0.15 | 0.15 | 0.18 | 0.25 | 0.48 | 0.60 | 0.65 | 0.62 | 0.61 |
| Tax % | 46.15% | 35.71% | 40.00% | -27.27% | -53.33% | 26.67% | 27.78% | 16.00% | 29.17% | 23.33% | 26.15% | 20.97% | |
| Net Profit | 0.07 | 0.10 | 0.09 | 0.14 | 0.23 | 0.12 | 0.13 | 0.21 | 0.34 | 0.46 | 0.49 | 0.50 | 0.48 |
| EPS in Rs | 0.15 | 0.22 | 0.20 | 0.31 | 0.50 | 0.26 | 0.28 | 0.46 | 0.74 | 1.01 | 1.07 | 1.09 | 1.05 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 42.86% | -10.00% | 55.56% | 64.29% | -47.83% | 8.33% | 61.54% | 61.90% | 35.29% | 6.52% | 2.04% |
| Change in YoY Net Profit Growth (%) | 0.00% | -52.86% | 65.56% | 8.73% | -112.11% | 56.16% | 53.21% | 0.37% | -26.61% | -28.77% | -4.48% |
Colinz Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -3% |
| 3 Years: | -2% |
| TTM: | -8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 31% |
| 3 Years: | 14% |
| TTM: | -6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 40% |
| 3 Years: | 3% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 5% |
| 3 Years: | 6% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 3:01 pm
Balance Sheet
Last Updated: September 10, 2025, 3:23 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.55 | 3.55 | 2.52 | 2.52 | 2.52 |
| Reserves | 2.78 | 2.62 | 2.71 | 2.98 | 3.21 | 3.30 | 3.29 | 3.75 | 4.14 | 5.62 | 6.43 | 6.96 |
| Borrowings | 1.88 | 2.53 | 1.80 | 0.76 | 0.42 | 0.68 | 0.38 | 0.99 | 0.48 | 0.27 | 0.57 | 0.64 |
| Other Liabilities | 1.79 | 1.97 | 1.70 | 2.40 | 2.42 | 1.65 | 1.60 | 1.81 | 1.76 | 1.82 | 1.84 | 1.70 |
| Total Liabilities | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 |
| Fixed Assets | 3.72 | 3.16 | 2.88 | 2.63 | 2.41 | 2.21 | 2.06 | 2.03 | 1.86 | 1.71 | 1.58 | 1.70 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.32 | 0.29 | 0.29 | 0.41 | 0.53 | 0.50 | 0.36 | 0.61 | 0.67 | 0.66 | 1.02 | 1.04 |
| Other Assets | 5.95 | 7.21 | 6.58 | 6.64 | 6.65 | 6.46 | 6.39 | 7.46 | 7.40 | 7.86 | 8.76 | 9.08 |
| Total Assets | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 |
Below is a detailed analysis of the balance sheet data for Colinz Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 2.52 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 2.52 Cr..
- For Reserves, as of Mar 2025, the value is 6.96 Cr.. The value appears strong and on an upward trend. It has increased from 6.43 Cr. (Mar 2024) to 6.96 Cr., marking an increase of 0.53 Cr..
- For Borrowings, as of Mar 2025, the value is 0.64 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.57 Cr. (Mar 2024) to 0.64 Cr., marking an increase of 0.07 Cr..
- For Other Liabilities, as of Mar 2025, the value is 1.70 Cr.. The value appears to be improving (decreasing). It has decreased from 1.84 Cr. (Mar 2024) to 1.70 Cr., marking a decrease of 0.14 Cr..
- For Total Liabilities, as of Mar 2025, the value is 11.82 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.36 Cr. (Mar 2024) to 11.82 Cr., marking an increase of 0.46 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1.70 Cr.. The value appears strong and on an upward trend. It has increased from 1.58 Cr. (Mar 2024) to 1.70 Cr., marking an increase of 0.12 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 1.04 Cr.. The value appears strong and on an upward trend. It has increased from 1.02 Cr. (Mar 2024) to 1.04 Cr., marking an increase of 0.02 Cr..
- For Other Assets, as of Mar 2025, the value is 9.08 Cr.. The value appears strong and on an upward trend. It has increased from 8.76 Cr. (Mar 2024) to 9.08 Cr., marking an increase of 0.32 Cr..
- For Total Assets, as of Mar 2025, the value is 11.82 Cr.. The value appears strong and on an upward trend. It has increased from 11.36 Cr. (Mar 2024) to 11.82 Cr., marking an increase of 0.46 Cr..
Notably, the Reserves (6.96 Cr.) exceed the Borrowings (0.64 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.54 | -2.07 | -1.35 | -0.35 | -0.07 | -0.33 | -0.07 | -0.65 | 0.11 | 0.36 | -0.03 | -0.15 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65.51 | 62.53 | 60.83 | 66.65 | 78.31 | 80.79 | 72.22 | 77.03 | 63.36 | 57.69 | 44.65 | 36.89 |
| Inventory Days | 188.53 | 288.96 | 232.18 | 267.25 | 266.31 | 246.80 | 225.13 | 208.33 | 147.59 | 149.17 | 134.31 | 136.22 |
| Days Payable | 93.17 | 116.24 | 60.66 | 55.68 | 91.93 | 44.16 | 49.29 | 90.00 | 76.17 | 103.15 | 94.81 | 94.31 |
| Cash Conversion Cycle | 160.87 | 235.25 | 232.35 | 278.23 | 252.70 | 283.42 | 248.06 | 195.36 | 134.78 | 103.71 | 84.15 | 78.81 |
| Working Capital Days | 89.65 | 110.24 | 100.04 | 71.19 | 72.72 | 89.45 | 79.01 | 0.00 | 9.95 | 11.23 | -22.84 | 72.66 |
| ROCE % | 2.51% | 3.20% | 3.23% | 3.00% | 3.18% | 3.40% | 3.39% | 4.39% | 6.80% | 8.08% | 7.70% | 6.72% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.97 | 1.93 | 1.82 | 0.74 | 0.99 |
| Diluted EPS (Rs.) | 1.97 | 1.93 | 1.82 | 0.74 | 0.99 |
| Cash EPS (Rs.) | 2.49 | 2.45 | 2.33 | 1.52 | 0.58 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 37.61 | 35.52 | 32.31 | 21.68 | 20.57 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 37.61 | 35.52 | 32.31 | 21.68 | 20.57 |
| Revenue From Operations / Share (Rs.) | 25.91 | 27.91 | 28.40 | 19.67 | 17.37 |
| PBDIT / Share (Rs.) | 3.15 | 3.25 | 3.10 | 2.13 | 0.93 |
| PBIT / Share (Rs.) | 2.63 | 2.73 | 2.59 | 1.57 | 0.93 |
| PBT / Share (Rs.) | 2.46 | 2.58 | 2.38 | 1.35 | 0.69 |
| Net Profit / Share (Rs.) | 1.97 | 1.93 | 1.81 | 0.95 | 0.58 |
| PBDIT Margin (%) | 12.14 | 11.63 | 10.91 | 10.85 | 5.38 |
| PBIT Margin (%) | 10.13 | 9.78 | 9.11 | 7.96 | 5.38 |
| PBT Margin (%) | 9.48 | 9.25 | 8.38 | 6.88 | 3.98 |
| Net Profit Margin (%) | 7.60 | 6.92 | 6.39 | 4.86 | 3.37 |
| Return on Networth / Equity (%) | 5.24 | 5.43 | 5.61 | 4.41 | 2.84 |
| Return on Capital Employeed (%) | 6.85 | 7.49 | 7.81 | 6.99 | 4.41 |
| Return On Assets (%) | 4.20 | 4.28 | 4.47 | 3.41 | 2.05 |
| Total Debt / Equity (X) | 0.06 | 0.06 | 0.03 | 0.06 | 0.13 |
| Asset Turnover Ratio (%) | 0.56 | 0.65 | 0.70 | 0.69 | 0.65 |
| Current Ratio (X) | 4.17 | 4.00 | 4.15 | 3.72 | 2.82 |
| Quick Ratio (X) | 3.81 | 3.62 | 3.66 | 3.26 | 2.34 |
| Inventory Turnover Ratio (X) | 0.68 | 0.56 | 0.66 | 0.55 | 0.37 |
| Interest Coverage Ratio (X) | 18.70 | 21.98 | 14.93 | 10.03 | 3.83 |
| Interest Coverage Ratio (Post Tax) (X) | 12.71 | 14.08 | 9.75 | 5.49 | 3.40 |
| Enterprise Value (Cr.) | 13.34 | 3.03 | 3.36 | 3.63 | -0.99 |
| EV / Net Operating Revenue (X) | 2.04 | 0.43 | 0.46 | 0.52 | -0.16 |
| EV / EBITDA (X) | 16.82 | 3.70 | 4.30 | 4.79 | -3.00 |
| MarketCap / Net Operating Revenue (X) | 2.80 | 1.35 | 1.23 | 1.20 | 0.43 |
| Price / BV (X) | 1.93 | 1.06 | 1.08 | 1.09 | 0.36 |
| Price / Net Operating Revenue (X) | 2.80 | 1.35 | 1.23 | 1.20 | 0.43 |
| EarningsYield | 0.02 | 0.05 | 0.05 | 0.04 | 0.07 |
After reviewing the key financial ratios for Colinz Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. It has increased from 1.93 (Mar 24) to 1.97, marking an increase of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. It has increased from 1.93 (Mar 24) to 1.97, marking an increase of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.49. This value is below the healthy minimum of 3. It has increased from 2.45 (Mar 24) to 2.49, marking an increase of 0.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 37.61. It has increased from 35.52 (Mar 24) to 37.61, marking an increase of 2.09.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 37.61. It has increased from 35.52 (Mar 24) to 37.61, marking an increase of 2.09.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 25.91. It has decreased from 27.91 (Mar 24) to 25.91, marking a decrease of 2.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.15. This value is within the healthy range. It has decreased from 3.25 (Mar 24) to 3.15, marking a decrease of 0.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.63. This value is within the healthy range. It has decreased from 2.73 (Mar 24) to 2.63, marking a decrease of 0.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.46. This value is within the healthy range. It has decreased from 2.58 (Mar 24) to 2.46, marking a decrease of 0.12.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 2. It has increased from 1.93 (Mar 24) to 1.97, marking an increase of 0.04.
- For PBDIT Margin (%), as of Mar 25, the value is 12.14. This value is within the healthy range. It has increased from 11.63 (Mar 24) to 12.14, marking an increase of 0.51.
- For PBIT Margin (%), as of Mar 25, the value is 10.13. This value is within the healthy range. It has increased from 9.78 (Mar 24) to 10.13, marking an increase of 0.35.
- For PBT Margin (%), as of Mar 25, the value is 9.48. This value is below the healthy minimum of 10. It has increased from 9.25 (Mar 24) to 9.48, marking an increase of 0.23.
- For Net Profit Margin (%), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 7.60, marking an increase of 0.68.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.24. This value is below the healthy minimum of 15. It has decreased from 5.43 (Mar 24) to 5.24, marking a decrease of 0.19.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.85. This value is below the healthy minimum of 10. It has decreased from 7.49 (Mar 24) to 6.85, marking a decrease of 0.64.
- For Return On Assets (%), as of Mar 25, the value is 4.20. This value is below the healthy minimum of 5. It has decreased from 4.28 (Mar 24) to 4.20, marking a decrease of 0.08.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.06.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has decreased from 0.65 (Mar 24) to 0.56, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 4.17. This value exceeds the healthy maximum of 3. It has increased from 4.00 (Mar 24) to 4.17, marking an increase of 0.17.
- For Quick Ratio (X), as of Mar 25, the value is 3.81. This value exceeds the healthy maximum of 2. It has increased from 3.62 (Mar 24) to 3.81, marking an increase of 0.19.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 4. It has increased from 0.56 (Mar 24) to 0.68, marking an increase of 0.12.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 18.70. This value is within the healthy range. It has decreased from 21.98 (Mar 24) to 18.70, marking a decrease of 3.28.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.71. This value is within the healthy range. It has decreased from 14.08 (Mar 24) to 12.71, marking a decrease of 1.37.
- For Enterprise Value (Cr.), as of Mar 25, the value is 13.34. It has increased from 3.03 (Mar 24) to 13.34, marking an increase of 10.31.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.04. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 2.04, marking an increase of 1.61.
- For EV / EBITDA (X), as of Mar 25, the value is 16.82. This value exceeds the healthy maximum of 15. It has increased from 3.70 (Mar 24) to 16.82, marking an increase of 13.12.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.80. This value is within the healthy range. It has increased from 1.35 (Mar 24) to 2.80, marking an increase of 1.45.
- For Price / BV (X), as of Mar 25, the value is 1.93. This value is within the healthy range. It has increased from 1.06 (Mar 24) to 1.93, marking an increase of 0.87.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.80. This value is within the healthy range. It has increased from 1.35 (Mar 24) to 2.80, marking an increase of 1.45.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.02, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Colinz Laboratories Ltd:
- Net Profit Margin: 7.6%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.85% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.24% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.71
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.81
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 37.8 (Industry average Stock P/E: 50.39)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.6%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-101, Pratik Ind.Estate, Mulund-Goregaon Link Road, Mumbai Maharashtra 400078 | colinzlabs@yahoo.com http://www.findoc-cll.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. N K Menon | Whole Time Director |
| CA. Vasant K Bhat | Independent Director |
| Mr. A Krishna Kumar | Independent Director |
| Dr. Mani L S | Non Executive Director |
| CA. Bhavik Ashokkumar Shah | Addnl. & Ind.Director |
| Mr. Baptist Bernard Dias | Addnl. & Ind.Director |
FAQ
What is the intrinsic value of Colinz Laboratories Ltd?
Colinz Laboratories Ltd's intrinsic value (as of 29 October 2025) is 34.67 which is 12.89% lower the current market price of 39.80, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 18.2 Cr. market cap, FY2025-2026 high/low of 88.7/37.6, reserves of ₹6.96 Cr, and liabilities of 11.82 Cr.
What is the Market Cap of Colinz Laboratories Ltd?
The Market Cap of Colinz Laboratories Ltd is 18.2 Cr..
What is the current Stock Price of Colinz Laboratories Ltd as on 29 October 2025?
The current stock price of Colinz Laboratories Ltd as on 29 October 2025 is 39.8.
What is the High / Low of Colinz Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Colinz Laboratories Ltd stocks is 88.7/37.6.
What is the Stock P/E of Colinz Laboratories Ltd?
The Stock P/E of Colinz Laboratories Ltd is 37.8.
What is the Book Value of Colinz Laboratories Ltd?
The Book Value of Colinz Laboratories Ltd is 20.7.
What is the Dividend Yield of Colinz Laboratories Ltd?
The Dividend Yield of Colinz Laboratories Ltd is 0.00 %.
What is the ROCE of Colinz Laboratories Ltd?
The ROCE of Colinz Laboratories Ltd is 6.72 %.
What is the ROE of Colinz Laboratories Ltd?
The ROE of Colinz Laboratories Ltd is 5.43 %.
What is the Face Value of Colinz Laboratories Ltd?
The Face Value of Colinz Laboratories Ltd is 10.0.